- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05533463
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
November 3, 2023 updated by: Jiangsu HengRui Medicine Co., Ltd.
Phase I Study to Evaluate the Safety ,Tolerability, and Pharmacokinetics of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
The study is being conducted to evaluate the safety and tolerability of HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation.To estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose [RP2D]) within investigated subject population groups
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
108
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wei Shi
- Phone Number: +021-61053363
- Email: wei.shi@hengrui.com
Study Locations
-
-
Shanghai
-
ShangHai, Shanghai, China, 200433
- Recruiting
- Shanghai Pulmonary Hospital
-
Principal Investigator:
- Caicun Zhou
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.
- Male or female ≥ 18 years old.
- Histologically confirmed diagnosis of advanced solid tumor harbouring with KRAS G12D mutation
- ECOG performance status of 0-1.
- With a life expectancy of ≥3 months.
- Have at least one measurable lesion.
- Adequate laboratory parameters during the screening period
Exclusion Criteria:
- Previously received KRAS G12D inhibitors
- Priot radiotherapy within 28 days for non-thoracic radiation
- Prior anti-tumor chemotherapy (< 6 weeks if chemotherapy including nitrosoureas or mitomycin) within 4 weeks before the study drug administration
- Any unresolved AEs > Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or inclusion/exclusion criteria level (The investigators determined that safe and controllable toxicity was excluded, such as alopecia and ≤ grade 2 peripheral neuropathy ).
- Central nervous system (CNS) metastases
- Major surgical therapy within 28 days prior to the date of signature of informed consent form, or expected major surgery during the study.
- Known history of hypersensitivity to any components of HRS-4642.
- Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HRS-4642
In Dose Escalation: HRS-4642 will be injected QW. Six dose levels are preset. In Dose Expansion: 1 to 2 dose cohorts will be selected for dose expansion stage. In Indication Expansion: Enrollment into the dose expansion cohorts may be from any eligible solid tumor type. |
HRS-4642 will be administrated per dose level in which the patients are assigned.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety endpoints: adverse events(AEs), serious adverse events(SAEs).
Time Frame: 24 months
|
Assess safety and tolerability of HRS-4642 by way of adverse events (CTCAE v5.0).
|
24 months
|
Dose Limited Toxicity(DLT)
Time Frame: from day 1 to Day 21
|
A DLT is defined as any event meeting the DLT criteria occurring within 21 days of first dose on Cycle 1 Day 1 (C1D1), excluding toxicities clearly related to disease progression or intercurrent illness
|
from day 1 to Day 21
|
Maximum tolerated dose (MTD)
Time Frame: From Day 1 to Day 21
|
Incidence and category of dose limiting toxicities (DLTs) during the first 21-day cycle of HRS-4642 treatment.
|
From Day 1 to Day 21
|
RP2D
Time Frame: 24 months
|
RP2D will be determined on the basis of evaluation on safety, PK, efficacy data in dose escalation and dose expansion stages.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Abnormal Laboratory Values
Time Frame: 24months.
|
24months.
|
|
Number of subjects with clinically significant changes in ECOG, vital signs and physical examination.
Time Frame: 24months.
|
24months.
|
|
Number of subjects with changes on ECG.
Time Frame: 24months.
|
24months.
|
|
Efficacy endpoints: Overall response rate (ORR).
Time Frame: 24months.
|
Evaluated by RECIST v1.1.
|
24months.
|
Efficacy endpoints: Duration of response (DoR).
Time Frame: 24 months.
|
Evaluated by RECIST v1.1
|
24 months.
|
Efficacy endpoints: Disease control rate (DCR).
Time Frame: 24months.
|
Evaluated by RECIST v1.1.
|
24months.
|
Efficacy endpoints: Progression free survival (DoR).
Time Frame: 24months.
|
Evaluated by RECIST v1.1.
|
24months.
|
Efficacy endpoints: overall survival (OS).
Time Frame: 24minths
|
Evaluated by RECIST v1.1
|
24minths
|
Cmax.
Time Frame: 24 months.
|
Maximal plasma concentration.
|
24 months.
|
Tmax.
Time Frame: 24 months
|
Time to Cmax.
|
24 months
|
AUC.
Time Frame: 24 months.
|
Area under the plasma concentration-time curve.
|
24 months.
|
t1/2.
Time Frame: 24 months.
|
Terminal-phase elimination half-life.
|
24 months.
|
Vz/F.
Time Frame: 24 months.
|
Apparent volume of distribution during terminal phase after non-intravenous administration.
|
24 months.
|
CL/F.
Time Frame: 24 months.
|
Apparent total clearance of the drug from plasma after oral administration.
|
24 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 15, 2022
Primary Completion (Estimated)
April 30, 2024
Study Completion (Estimated)
December 30, 2024
Study Registration Dates
First Submitted
September 5, 2022
First Submitted That Met QC Criteria
September 5, 2022
First Posted (Actual)
September 9, 2022
Study Record Updates
Last Update Posted (Actual)
November 7, 2023
Last Update Submitted That Met QC Criteria
November 3, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRS-4642-I-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced KRAS G12D Mutant Solid Tumors
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced KRAS G12D Mutant Solid TumorsChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingKRAS G12C Mutant Advanced Solid TumorsChina
-
AmgenActive, not recruitingKRAS p.G12C Mutant Advanced Solid TumorsUnited States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
-
Chinese PLA General HospitalZhejiang UniversityRecruitingSolid Tumor, Adult | KRAS G12D | EphA2 Overexpression | KRAS G12V | KRAS G12CChina
-
Providence Health & ServicesAvailableKRAS G12V Mutant Advanced Epithelial Cancers
-
Suzhou Genhouse Bio Co., Ltd.Shanghai East Hospital; Shandong Tumor HospitalRecruitingAdvanced Solid Tumors With MAPK Signal Pathway MutantChina
-
Lupin Ltd.CompletedA Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid TumorsNRAS/KRAS Mutated Advanced or Metastatic Refractory Solid TumorsUnited Kingdom, Netherlands, Belgium
-
AmgenActive, not recruitingAdvanced/Metastatic Solid Tumors With KRAS p.G12C MutationTaiwan, Hong Kong
-
Turning Point Therapeutics, Inc.TerminatedAdvanced Solid Tumor | Metastatic Solid Tumor | KRAS Mutation-Related TumorsUnited States
-
Boehringer IngelheimCompletedSolid Tumors, KRAS MutationJapan
Clinical Trials on HRS-4642
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruitingAdvanced Malignant Tumour
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Guangdong Hengrui Pharmaceutical Co., LtdEnrolling by invitationRefractory Chronic CoughChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Grupo Español de Rehabilitación MultimodalUnknownArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipSpain
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced KRAS G12D Mutant Solid TumorsChina
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Guangdong Hengrui Pharmaceutical Co., LtdRecruitingChronic Obstructive Pulmonary DiseaseChina